In chronic myelogenous leukemia K562 cells FtH-silencing, by altering the redox metabolism, triggers p65 nuclear activation and resistance to doxorubicin (36). The gene discussed is FTH1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.